Tim Wallis, Founder and Managing Director, Ridgeway Biologicals Ltd

Emerging Company Showcase

1. Autogenous Vaccines in Principle and Practice An opportunity in Asia? Tim Wallis BSc PhD Ridgeway Biologicals Ltd, Units 1-3 Old Station Business Park, Compton, Berkshire, U.K. www.ridgewaybiologicals.co.uk

2. Why do we need autogenous vaccines? Bacteria are continuously evolving e mergence of new variants resulting in conventional vaccine breakdowns Changes in farming practices create newly susceptible populations e mergence of “new pathogens” n ew fully licensed products take 5yrs to develop Fully licenced vaccines not always available Autogenous vaccines can provide a rapid solution reduce dependence on antibiotics

3. Autogenous (emergency) vaccines - definitions Derived from pathogens isolated from the target farm/production system Inactivated vaccines Used where fully licensed products have proved ineffective or are unavailable Have to be manufactured in premises licenced by regulatory authorities Using QA assured manufacturing/QC processes Used under the supervision of veterinary surgeon

4. High specification manufacturing facility Resourced with committed team Strong Customer focus Highly skilled workforce Responsive vaccine manufacturing processes A daptable production scheduling Robust Quality Assurance “near cGMP” Strong R&D ethos

5. Pathogen submission/strain analysis I solation of pathogens pre- and post-sale Good liaison: Veterinary surgeon Expert local diagnostic laboratory Bacteriology Molecular biology Cell culture Virology Vaccine manufacturer

6. Autogenous vaccine products: poultry Pasteurella sp Riemerella anatipestifer Erysipelothrix rhusiopathiae Salmonella sp Mycoplasma gallisepticum Mycoplasma synoviae Gallibacterium anatis Ornithobacter rhinotrachealis E.coli Avian Influenza Newcastle disease Layers Broiler breeders Turkeys Ducks Geese Game birds Multivalent vaccines can simplify vaccination programs Vaccines adjuvated with oil or alhydrogel

7. Autogenous Vaccine products: Pigs Actinobacillus pleuropnumonia Haemophilus parasuis Salmonella species Streptococcus suis Brachyspira hyodysenteriae Mycoplasma hyosynoviae / hyorhinis / hyopneumoniae PRRS Swine flu

8. Autogenous vaccine products: aquatic species Vibrio species Tenacibaculum maritimus Flavo bacterium psychrophilum Yersinia ruckeri Pseudomonas anguillosepticum Photobacterium damseliae Aeromonas salmonicida Streptococcus species Nodavirus Viral Haemorrhagic Septicaemia Atlantic Cod Salmon Trout Sea Bass Tilapia Olive flounder Cleaner fish Display fish

9. Understanding route to Asian market Better understand: Veterinary medicines regulations State Veterinary health service provision Identify lead: Veterinary Diagnostic Laboratories Understand disease issues of main: Poultry broiler breeders Table egg producers Commercial duck producers Pig integrators Aquaculture sectors Target market priorities Develop the supply chain Logistically possible?

10. Autogenous vaccines: Summary (1) Fully licenced vaccines are not always available for the diseases of minor species Microbial pathogens are continuously evolving leading to the emergence of new strains Conventional vaccines are not always able to provide cross-protection against all variants of pathogens Autogenous vaccines are derived from farm-specific pathogens and can control new outbreak strains High quality products manufactured in regulated premises with defined and controlled processes

11. Autogenous vaccines: Summary (2) Formulated to the specific requirements of each client p lanning is required as they are bespoke products Rapid, adaptable response to new emerging infections Valuable resource for controlling infectious disease can help reduce dependence on antibiotics Not an alternative to good management, good nutrition and other prophylactic measures

12. Thanks for listening